Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2011 Jun 15;286(35):30535–30541. doi: 10.1074/jbc.M111.265413

Molecular Basis for the Interaction of Low Density Lipoprotein Receptor-related Protein 1 (LRP1) with Integrin αMβ2

IDENTIFICATION OF BINDING SITES WITHIN αMβ2 FOR LRP1*

Sripriya Ranganathan ‡,§, Chunzhang Cao ‡,, Jason Catania , Molly Migliorini , Li Zhang ‡,¶,1, Dudley K Strickland ‡,§,¶,2
PMCID: PMC3162413  PMID: 21676865

Abstract

The LDL receptor-related protein 1 (LRP1) is a large endocytic receptor that controls macrophage migration in part by interacting with β2 integrin receptors. However, the molecular mechanism underlying LRP1 integrin recognition is poorly understood. Here, we report that LRP1 specifically recognizes αMβ2 but not its homologous receptor αLβ2. The interaction between these two cellular receptors in macrophages is significantly enhanced upon αMβ2 activation by LPS and is mediated by multiple regions in both LRP1 and αMβ2. Specifically, we find that both the heavy and light chains of LRP1 are involved in αMβ2 binding. Within the heavy chain, the binding is mediated primarily via the second and fourth ligand binding repeats. For αMβ2, we find that the αM-I domain represents a major LRP1 recognition site. Indeed, substitution of the I domain of the αLβ2 receptor with that of αM confers the αLβ2 receptor with the ability to interact with LRP1. Furthermore, we show that residues 160EQLKKSKTL170 within the αM-I domain represent a major LRP1 recognition site. Given that perturbation of this specific sequence leads to altered adhesive activity of αMβ2, our finding suggests that binding of LRP1 to αMβ2 could alter integrin function. Indeed, we further demonstrate that the soluble form of LRP1 (sLRP1) inhibits αMβ2-mediated adhesion of cells to fibrinogen. These studies suggest that sLRP1 may attenuate inflammation by modulating integrin function.

Keywords: Adhesion, Fibrinogen, Integrin, Lipoprotein Receptor, Macrophages, LDL Receptor-related Protein 1, Soluble LRP1

Introduction

The LDL receptor-related protein 1 (LRP1)3 is a large endocytic receptor that recognizes numerous ligands (1, 2). LRP1 is synthesized as a single chain 600-kDa precursor that is processed by furin to generate a 515-kDa heavy chain and an 85-kDa light chain (3). The heavy chain contains four clusters of LDL receptor type A or “ligand binding” repeats, which are responsible for recognizing most of the ligands that bind to LRP1. The LRP1 light chain includes the transmembrane and cytoplasmic domain, which contains two NPxY motifs, and two dileucine repeats. The second NPxY motif overlaps with a YxxL motif, and along with the two dileucine repeats, contributes to LRP1 endocytosis (4).

In addition to binding soluble ligands, such as α2 macroglobulin-protease complexes (5) or various serpin-enzyme complexes (6), LRP1 also associates with other transmembrane proteins. These include the amyloid precursor protein (7, 8), the platelet-derived growth factor receptor-β (912), and β2 integrins (13, 14). The association of these cell surface transmembrane proteins with LRP1 alters their trafficking and functional properties. In the case of β2 integrins, Spijkers et al. (13) found that in U937 cells, αMβ2 co-precipitates with LRP1, which regulates its cell adhesion properties. Cao et al. (14) found that LRP1 co-localizes with αMβ2 at the trailing edge of migrating macrophages and further demonstrated that macrophage migration depends upon a coordinated effort between LRP1 and αMβ2 along with tissue plasminogen activator and its inhibitor, plasminogen activator inhibitor-1. Together, these studies reveal that LRP1 modulates the function of αMβ2.

To gain insight into the role of LRP1 in modulating αMβ2 function, it is necessary to define the molecular basis for the interaction between these two molecules. The objective of the current investigation was to identify regions on LRP1 and on αMβ2 that are important for mediating their interaction. To accomplish this, we employed LRP1 mini-receptors, and based on our observation that LRP1 interacts preferentially with αMβ2 but not αLβ2, we also employed homolog-scanning mutagenesis. In this process, regions from the αLβ2-I domain were swapped into the αMβ2-I domain within the heterodimeric receptor. Together, the results identify multiple determinants on LRP1 responsible for binding to αMβ2 and identify a region within the αMβ2-I domain that contributes to the interaction.

EXPERIMENTAL PROCEDURES

Materials and Antibodies

Hybridomas expressing the anti-Myc monoclonal 9E10, and the anti-αM-I domain antibodies LM2/1 and 44a were obtained from ATCC. Rabbit polyclonal antibody ARC22 directed against the cytoplasmic domain of the β2 subunit has been described (14). Monoclonal antibody 8G1 directed against human LRP1 has been described (5), and anti-LRP1 R2629 has been described (9). The αM-I domain was prepared as a fusion protein with GST as described (15). Prior to use, GST was removed by proteolysis to generate the free αM-I domain. Human kidney 293 cells stably expressing αMβ2 or αLβ2 were prepared as described (16, 17), whereas human kidney 293 cells expressing mutant αMβ2 or αLβ2 molecules were prepared as described (17). LRP1 mini-receptors were prepared as described (18). Receptor-associated protein (RAP) was prepared as described (19).

Transient Transfection of Human Kidney 293 Cells and Co-immunoprecipitation Experiments

Human kidney 293 cells stably transfected with αMβ2, αLβ2, or mutant forms of these integrins were grown to 70% confluency and transiently transfected using FuGENE® HD transfection reagent (5 μg of plasmid DNA/100-mm plate) with either N-terminal Myc-tagged LRP1 light chain (LC), N-terminal Myc-tagged mini LRP1 receptor containing the second cluster of ligand binding repeats (mLRP-II), N-terminal Myc-tagged mini LRP1 receptor containing the fourth cluster of ligand binding repeats (mLRP-IV), or vector control. 40 h following transfection, cell lysates were prepared by adding lysis buffer (50 mm Tris, 150 mm NaCl, 1% Nonidet P-40) containing protease and phosphatase inhibitors. Lysates were precleared with nonimmune IgG-protein G-Sepharose and immunoprecipitated overnight with anti-Myc monoclonal 9E10 IgG (7.5 μg/ml) and protein G-Sepharose. After washing in lysis buffer three times, the immunoprecipitates were separated on 4–12% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were probed for β2 subunit using ARC22 (1 μg/ml). To measure the immunoprecipitated LRP1, the blots were probed with 125I-labeled 9E10 IgG.

Binding of LRP1 to αM-I Domain

The purified αM-I domain was coated on 96-well flat-bottomed microtiter plates in 50 mm Tris and 150 mm NaCl (TBS) containing 2 mm CaCl2 overnight at 4 °C. The wells were then washed with 1% BSA in TBS and 2 mm CaCl2 for 1 h at room temperature. Increasing concentrations of purified LRP1 were then added in 1% BSA, TBS, 2 mm CaCl2, and 0.05% Tween 20 and were allowed to incubated overnight at 4 °C with the immobilized αM-I domain. Following washing, bound LRP1 was detected with monoclonal antibody 8G1 (0.5 μg/ml) and horseradish peroxidase-conjugated goat anti-mouse IgG antibody. Wells were developed using tetramethylbenzidine peroxidase substrate (KPL, Gaithersburg, MD), and absorbance was measured at 590 nm. The binding data were fit to a binding model with a single class of sites using nonlinear regression analysis using SigmaPlot software as described (20).

Purification of Soluble LRP1 (sLRP1)

sLRP1 was purified from human plasma by affinity chromatography over monoclonal antibody 8G1-Sepharose followed by ion-exchange chromatography over a Mono-Q anion exchange column. Briefly, 1 liter of fresh frozen plasma was thawed, and the following were added: 1 mm CaCl2, 1 μm Phe[D]-Pro-Arg-chloromethylketone, 20 μg/ml PMSF, 40 μg/ml pepstatin, 1.25 μg/ml leupeptin, and 10 μg/ml benzamidine. The plasma was applied to a 5-ml Sepharose Cl 6B precolumn and then applied to a 10-ml 8G1-Sepharose column. The column was washed with TBS, pH 7.5, 20 mm EDTA and then washed with TBS, pH 7.5, containing 1 mm CaCl2. sLRP1 was eluted with 0.1 m sodium acetate, 0.5 m NaCl, pH 4.5. The sLRP1 was then applied to a mono-Q anion exchange column and eluted as described previously for full-length LRP1 (21).

Adhesion Assays

24-Well non-tissue culture polystyrene plates were coated with fibrinogen (100 μl, 50 μg/ml). After 90 min at 22 °C, 400 μl of blocking buffer (1% BSA containing 0.05% polyvinyl-pyrrolidone in PBS) was added. After washing twice with PBS, 2 × 106 293 cells stably transfected with αMβ2 in 400 μl of Hank's buffered salt solution containing 5 mm HEPES, 1 mm CaCl2, and 1 mm MgCl2 were incubated with or without sLRP1 (20 nm) for 10 min at room temperature. The cells were then added to fibrinogen-coated wells. After incubating at 37 °C for 30 min, non-adherent cells were removed by washing. The number of adherent cells were quantified by crystal violet staining and measuring the absorbance at 570 nm.

Effect of Integrin Activation of Association with LRP1

Thioglycolate-ellicited macrophages were placed into four different tubes (2.5 × 106 cells/tube). Two tubes were placed on ice and served as control cells. LPS (500 ng/ml) was added to the remaining two tubes, which were then incubated at 37 °C for 30 min. Cell extracts from all four tubes were used for immunoprecipitation with 10 μg of mouse IgG as a control or 10 μg of anti-LRP1 monoclonal antibody 5A6. Following immunoprecipitation, proteins were separated on a 4–12% Tris glycine gel and analyzed for the presence of β2 integrin and LRP1 by immunoblot analysis.

Measurement of αMβ2 Internalization in LRP1-expressing and LRP1-deficient Macrophages

Mice with LRP1 deleted in macrophages, macLRP1−/−, were generated by crossing LysMCre mice (22) (kindly provided by I. Förster) with LRP1flox/flox mice (23) (kindly provided by J. Herz) as described (24). To prepare primary macrophages, bone marrow was flushed from the femur and tibia with DMEM medium and dispersed into single-cell suspension. After lysis of red blood cells with ammonium chloride (8.3 g/liter in 10 mm Tris-HCl, pH 7.4), bone marrow cells were plated in 10-cm tissue culture Petri dishes in DMEM/10% fetal bovine serum and incubated in a humidified incubator with 5% CO2 at 37 °C for 2 to 4 h. Suspension cells were collected and cultured in 10-cm Petri dishes at a density of 2 × 105 cells/ml in DMEM with 10% FBS and 10% L929 cell-conditioned medium at 37 °C and 5% CO2 for 7 days. The maturity and purity of the differentiated macrophages were verified by flow cytometry based on their positive staining for F4/80 and M1/70, and negative staining for CD11c and by morphological examination of Hema3 (Fisher Scientific)-stained Cytospin (Shandon) smears. Internalization of αMβ2 was performed using FACS analysis as described (14). Briefly, 106 macrophages in Hank's balanced salt solution plus 1 mm Mg2+ were incubated with 10 ng/ml LPS and then stained with mAb M1/70 for 60 min at 4 °C. The temperature was then raised to 37 °C for indicated time periods to allow integrin internalization. At the indicated times, the cells were chilled to 4 °C. αMβ2 remaining on the cell surface was measured by using an Alexa 488 conjugate of anti-rat IgG at 4 °C. Single color FACS analysis was performed for WT and deficient cells using FACScan (Becton-Dickinson), counting 10,000 events. Mean fluorescence intensities were quantitated by FACS using the FACScan Program.

RESULTS

Multiple Determinants within LRP1 Are Involved in Interaction with αMβ2

To identify regions within LRP1 that are responsible for interacting with αMβ2, we used LRP1 mini-receptors (Fig. 1A), which have been successfully employed to map out ligand binding sites for this receptor (18, 25). Human kidney 293 cells stably expressing αMβ2 (17) were transfected with empty vector, or plasmids expressing the LRP1 light chain (LC), LRP1 mini-receptor II (mLRP-II) or LRP1 mini-receptor IV (mLRP-IV). Following transfection, cell lysates were subjected to immunoprecipitation using anti-Myc IgG. The immunoprecipitates were then analyzed by immunoblotting with ARC22, an antibody specific for the β2 subunit (14). The results (Fig. 1B) reveal that αMβ2 co-immunoprecipitates with the LRP1 LC as well as mLRP-II and mLRP-IV. To confirm that the LRP1 constructs were expressed, the immunoblots were also probed with 125I-labeled 9E10 (Fig. 1B, middle panel). These results reveal a somewhat lower expression of mLRP-II and mLRP-IV when compared with the LC, and from this, we concluded that the LRP1 LC binds more weakly to αMβ2 than do the LRP1 constructs that express the clusters of ligand binding repeats. These data reveal that determinants within the LRP1 ectodomain play a major role in interacting with αMβ2, whereas determinants within the LRP1 LC contribute less to the binding interaction.

FIGURE 1.

FIGURE 1.

αMβ2 associates with LRP1 mini-receptors and the 85-kDa LRP1 subunit. A, diagram demonstrating the full-length LRP1 molecule, LC, mLRP-II, and mLRP-IV. B and C, human kidney 293 cells stably expressing αMβ2 were transfected with empty vector, or plasmids expressing the LC, mLRP-II, or mLRP-IV (B) or plasmids expressing the LRP1 LC and mutant forms of the light chain (C). Following transfection, cell lysates were immunoprecipitated with anti-Myc IgG, and the immunoprecipitated proteins were analyzed by immunoblotting with ARC22, an antibody specific for the β2 subunit (upper panels). Total LC and mLRP immunoprecipitated was detected by incubating the blot with 125I-labeled 9E10 (middle panels). Cell lysates were also immunoblotted for β2 levels (bottom panels). Data shown are representative of three independent experiments. psec, empty plasmid; WB, Western blot.

Because the LRP1 LC contains two NPxY motifs that are recognized by a number of adaptor proteins (26), which in turn, may also interact with the integrin cytoplasmic domain, we performed experiments using various mutant LC molecules in which either the first NPxY motif (NPxY-1) or second NPxY (NPxY-2) motifs were mutated. We also used a mutant LC, termed 16T3S, in which the serine and threonine phosphorylation sites on the LC were mutated (27). The results from this experiment (Fig. 1C) reveal that αMβ2 co-immunoprecipitated with all of the mutant LC molecules as effectively as WT LC suggesting that the NPxY motifs do not appear to contribute to integrin binding.

LRP1 Appears Specific for αMβ2 and Does Not Interact with αLβ2

To identify regions on αMβ2 that interact with LRP1, we first examined whether LRP1 is also capable of interacting with αLβ2. Similar to the αM subunit, the αL subunit also contains an I domain, which has been implicated in the binding of ligands to these integrins (28, 29). Human kidney 293 cells stably expressing either αMβ2 or αLβ2 were transfected with constructs expressing either the LC, mini-LRP1-II, or mini-LRP1-IV, and co-immunoprecipitation experiments were performed. The results confirm the experiments in Fig. 1, revealing that αMβ2 co-immunoprecipitates with the LRP1 LC as well as mLRP1-II and mLRP1-IV (Fig. 2A). In contrast, we note very little co-immunoprecipitation of αLβ2 with the LRP1 LC or with mLRP1-II and mLRP1-IV (Fig. 2B). This is not due to low expression of αLβ2 in the transfected cells, as immunoblot analysis using a β2-specific antibody confirmed expression of αLβ2 in the transfected cells (Fig. 2B, lower panel). These results are in contrast to those reported earlier (13), where LRP1 was reported to also associate with αLβ2.

FIGURE 2.

FIGURE 2.

The interaction of LRP1 mini receptors with β2 integrins is specific for αMβ2. Human kidney 293 cells stably expressing either αMβ2 (A) or αLβ2 (B) were transfected with constructs expressing the LC, mLRP-II, or mLRP-IV. Following transfection, LC, mLRP-II, and mLRP-IV were precipitated with anti-Myc IgG, and immunoprecipitated proteins were analyzed for β2 subunit by immunoblot analysis (upper panels). Total LC and mLRP immunoprecipitated was detected by incubating the blot with fluorescently labeled 9E10 (FL-9E10; middle panels). Cell lysates were also immunoblotted for β2 levels (bottom panels). Data shown are representative of three independent experiments. psec, empty plasmid.

LRP1 Binds to Purified αM-I Domain

The αM-I domain is responsible for interacting with numerous ligands, including ICAM-1, fibrinogen, C3bi, and neutrophil inhibitory factor, and thus could mediate the interaction of αMβ2 with LRP1. To determine whether LRP1 recognizes this portion of the integrin, solid phase assays were performed in which the purified αM-I domain was first coated to microtiter wells, and then increasing concentrations of purified LRP1 were added to the wells. The results (Fig. 3A) reveal a tight association of purified LRP1 with microtiter wells coated with the αM-I domain. Nonlinear regression analysis was employed to estimate an apparent KD of 46 nm. As expected, no binding of LRP1 to microtiter wells coated with BSA was detected. As an additional control for these experiments, we also measured the binding of two well characterized conformation-dependent antibodies to the αM-I domain: antibody LM2/1 (30) and 44a (31). The results (Fig. 3B) reveal that both of these antibodies bind avidly to the immobilized αM-I domain, confirming the integrity of the recombinant αM-I domain. In summary, these studies confirm that the αM-I domain is recognized by LRP1.

FIGURE 3.

FIGURE 3.

LRP1 binds to immobilized αM-I domain. A, microtiter wells were coated with the αM-I domain, blocked with BSA, and then incubated with increasing concentrations of purified human LRP1. The amount of LRP1 bound following washing was determined using monoclonal antibody 8G1. As a control, the binding of LRP1 to BSA-coated wells was also measured. The solid curve represents the best fit to a binding isotherm as determined by nonlinear regression analysis. B, binding of monoclonal antibodies LM2/1 and 44A to microtiter wells coated with the αM-I domain (closed symbols) or BSA as a control (open symbols). Data shown are representative of two independent experiments.

Reconstruction of LRP1 Binding Site in αLβ2

The demonstration that αLβ2 does not co-precipitate with mini-receptors of LRP1 afforded the opportunity to test the hypothesis that replacing the αL-I domain with that from αM might restore, at least partially, the LRP1 binding site in the integrin. To test this hypothesis, we used human kidney 293 cells stably transfected with a mutant αLβ2 molecule in which the αL-I domain was replaced with that from αM. The results, shown in Fig. 4, reveal that the hybrid integrin αL(I/αM2 co-immunoprecipitated with mLRP-IV, although not to the same extent seen with αMβ2. These results confirm that the αM-I domain contributes to LRP1 binding. The lack of complete restoration of binding by I domain replacement suggests that other regions within the αMβ2 molecule also are involved in binding to LRP1.

FIGURE 4.

FIGURE 4.

Grafting the αM-I domain into αLβ2 to create the chimeric αL(I/αM2 receptor restores LRP1 binding. Human kidney 293 cells stably expressing αMβ2, αL(I/αM2, or αLβ2 were transfected with vector or mLRP-IV. Following transfection, mLRP-IV was precipitated with anti-Myc IgG, and immunoprecipitated proteins were analyzed for the β2 subunit by immunoblot analysis (upper panel). The amount of total mLRP-IV immunoprecipitated was measured by incubating the blot with fluorescently labeled 9E10 (FL-9E10; middle panel). Cell lysates were also immunoblotted for β2 levels (bottom panel). Data shown are representative of two independent experiments. WB, Western blot.

Homolog-scanning Mutagenesis Identifies Region on I Domain That Interacts with LRP1

Our prior work investigating the binding of the RAP D3 domain to LRP1 demonstrated an essential role of lysines 256 and 270 in this interaction (32). These two lysine residues are located 21 Å apart on helix α8 of RAP (33). A crystal structure of the RAP D3 domain with two LDLa repeats from the LDL receptor revealed that lysines 270 and 256 are each docked within acidic pockets located within the LDLa repeats (34) and provide a model for ligand binding to LRP1 in which lysine residues play a critical role. Thus, to locate binding sites within the αM-I domain, we focused on regions with surface exposed lysine residues. For these experiments, a homolog-scanning mutagenesis strategy was employed. This approach, which has been successfully utilized to identify the neutrophil inhibitory factor-binding site in the αM-I domain (17), involves switching segments within the αM-I domain with those from the αL-I domain. In the current investigation, we focused on regions that are rich in lysine. A loss of binding to mLRP1-IV was noted for a mutant, H1B, as assessed by co-immunoprecipitation analysis (Fig. 5A). In this mutant, residues 162–170 (EQLKKSKTL) were replaced with those (KKLSNTSYQ) from the αL-I domain. The structure (35) of the αM-I domain is shown in Fig. 5B, and residues 162–170 are located in a loop that connects the α1 helix with the B-β strand of the I domain (Fig. 5B, red).

FIGURE 5.

FIGURE 5.

Loss of LRP1 binding when Glu-160–Leu-170 in the αM-I domain is replaced with the corresponding sequence from αL-I domain. A, human kidney 293 cells stably expressing αMβ2 (WT) or the H1B mutant was transfected with either empty plasmid (Vector) or mLRP-IV. Following transfection, mLRP-IV was precipitated with anti-Myc IgG, and the immunoprecipitated proteins analyzed for the presence of the β2 subunit by immunoblot analysis (upper panel). Total mLRP-IV immunoprecipitated was measured incubating the blot with fluorescently labeled 9E10 (FL-9E10; middle panel). Cell lysates were also immunoblotted for β2 levels (bottom panel). B, three-dimensional structure of the αM-I domain (Protein Data Bank code 1IDO (35)) showing the location of Glu-160–Leu-170, which is colored red in the structure. This region contains three lysine residues (Lys-165, Lys-166, and Lys-168) that may be involved in the interaction of αM-I domain with LRP1. The figure was generated with PyMOL software.

αMβ2 Integrin Activation Enhances Its Interaction with LRP1

Treatment of macrophages with LPS increases the amount of αMβ2 integrin on the cell surface (36) and also leads to increased activation of the integrin (37). We conducted experiments to determine whether LPS treatment of macrophages would enhance the interaction of αMβ2 with LRP1. The results of this experiment reveal that a substantial increase in αMβ2 integrin co-immunoprecipitated with LRP1 when the cells were treated with LPS (Fig. 6A), revealing that integrin activation enhances the association of αMβ2 with LRP1.

FIGURE 6.

FIGURE 6.

LPS stimulation of macrophages increases association of αMβ2 with LRP1. A, peritoneal macrophages were incubated with or without LPS for 30 min at 37 °C prior to preparing cell extracts. Cell extracts were immunoprecipitated with control IgG or anti-LRP1 monoclonal 5A6, and the immunoprecipitated proteins were analyzed for the presence of the β2 subunit and for LRP1 by immunoblot analysis. B, cell extracts were analyzed for total β2 subunit and for LRP1 by immunoblot analysis. WB, Western blot.

LRP1 Modulates αMβ2 Integrin Function

To test the effect of LRP1 on the functional properties of αMβ2, we used soluble forms of LRP1 purified from plasma to measure the impact on adhesive properties of cells. In this experiment, 293 cells stably transfected with αMβ2 were preincubated with 20 nm sLRP1 prior to measuring their ability to adhere to fibrinogen-coated wells. The results of this experiment reveal that sLRP1 markedly reduces the adherence of these cells to fibrinogen (Fig. 7A).

FIGURE 7.

FIGURE 7.

LRP1 modulates αMβ2 function. A, 293 cells stably transfected with αMβ2 were incubated in the absence or presence of sLRP1 (20 nm). Following incubation, the ability of the cells to adhere to fibrinogen-coated wells was measured. *, p = 0.003. B, primary macrophages isolated from LRP1+/+ or macrophage-specific LRP1-deficient mice (macLRP1−/−) mice were analyzed for LRP1 expression by immunoblot analysis using antibody R2629. C, αMβ2 internalization upon incubation of macrophages with LPS (10 ng/ml) at 37 °C was measured by FACS analysis using an FITC conjugate of anti-rat IgG. The mean fluorescence intensity at time 0 was assigned 100%. The data shown represent the means ± S.D. of a duplicate experiment. *, p < 0.05.

Our prior work demonstrated that LRP1 and αMβ2 co-localize on the cell surface of primary macrophages and that RAP blocks the LPS-stimulated internalization of this integrin (14). As RAP is known to interact with virtually all LDL receptor family members and is thus not specific for LRP1, we used macrophages in which the Lrp1 gene was genetically deleted (24). In the current experiments, macrophages from WT or macLRP1−/− mice were employed. Immunoblot analysis confirmed effective deletion of LRP1 from macrophages (Fig. 7B). Upon LPS stimulation, ∼20% of αMβ2 was internalized in macrophages expressing LRP1. In contrast, no αMβ2 was internalized in macLRP1−/− macrophages, which lack LRP1 (Fig. 7C). These results establish that in macrophages, LRP1 is important for mediating the internalization of this integrin.

DISCUSSION

During an acute inflammatory response, macrophages accumulate at the injury site where they participate in wound repair processes. To complete this process, inflammation has to be resolved, which requires migration of macrophages from the injury site into the lymphatics in a process dependent upon αMβ2 (38). This process also appears to be regulated by LRP1, which associates with αMβ2 and alters the adhesive properties of this integrin (13) and modulates its ability to mediate cell migration (14). To gain insight into the interaction of LRP1 and αMβ2 at the molecular level, we initiated studies with LRP1 mini-receptors and with mutants of αMβ2. Our results identify several important insights regarding the interaction of LRP1 with β2 integrins and the functional consequences of this interaction.

First, our data suggest that LRP1 appears specific for αMβ2 and does not appear to associate with αLβ2. This is in contrast to the study by Spijkers et al. (13) who found that 500 nm recombinant αL-I domain bound to LRP1 immobilized onto a CM5-sensor chip. However, the potential interaction of full-length heterodimeric αLβ2 receptor expressed in mammalian cells with LRP1 was not investigated in the Spijkers et al. (13) study. It is thus possible that the interaction between LRP1 and the αL-I domain is of relatively low affinity, and thus, the weak interaction between αLβ2 and LRP1 is not detected readily by co-immunoprecipitation analysis.

Second, our data reveal that both mini-LRP-II and mini-LRP-IV, which contain the second and fourth ligand binding clusters of LRP1, respectively, bind avidly to αMβ2 as assessed by co-immunoprecipitation analysis. In addition, additional interactions are also evident between the LRP1 light chain and αMβ2. Together, these data suggest that the major interaction sites on LRP1 involve the ligand binding regions of this receptor but that additional interactions with determinants in the LRP1 light chain contribute to the interaction.

Third, our data reveal that LRP1 interacts with the αM-I domain and that this domain represents a major recognition interface. This was confirmed by binding studies using purified components, which revealed a high affinity interaction between LRP1 and the αM-I domain coated on microtiter wells. Furthermore, we were able to demonstrate binding in a gain-in-function experiment by generating a mutant αLβ2 in which the αM-I domain replaced the αL-I domain. By employing homolog-scanning mutagenesis (17) in which sequences within the αM-I domain were switched with those from αL-I domain, we identified a region corresponding to residues Glu-162 to Leu-170 that contribute to the LRP1 interaction. This region of αM-I domain is of interest, as Zhang and Plow (39) demonstrated that this loop region may represent a regulatory region that controls integrin activation and function. Indeed, these investigators demonstrated previously that perturbation of this specific sequence results in an enhanced adhesive activity of αMβ2 (39). Moreover, they showed that two function-blocking mAbs 44a and 2LPM19c inhibit the adhesive function of αMβ2 allosterically by binding to this same sequence (40). Interestingly, our studies confirm that sLRP1 inhibited αMβ2-mediated adhesion to fibrinogen. This effect occurred at relatively low concentrations of sLRP1 (20 nm). sLRP1 can be detected in the circulation at levels around 10 nm (41), and it has been documented that the levels of sLRP1 rise dramatically during inflammation (42). Thus, sLRP1 may represent a physiological mechanism to modulate macrophage function.

In summary, using molecular biology approaches, we have localized the functional regions within LRP1 and αMβ2 for their reciprocal recognition. We found that LRP1 binding to αMβ2 is mediated via multiple domains within both receptors. Most importantly, our results suggest the possibility that LRP1 regulates macrophage inflammatory activity by modulating the functions of αMβ2. Given the importance of LRP1-αMβ2 recognition in macrophage efflux and thus the resolution of acute inflammation, the information provided from this work may help us to better understand the role of LRP1 in inflammation. In this regard, conditional macrophage LRP1 knock-out mice exhibit proinflammatory phenotypes in animal models of atherosclerosis (43, 44). Thus, this work may help us understand the role of LRP1 and αMβ2 in macrophage-mediated inflammatory response, its proper resolution, and the initiation of wound healing.

*

This work was supported, in whole or in part, by National Institutes of Health Grants P01 HL054710 (to D. K. S. and L. Z.) and HL050784 and HL072929 (to D. K. S.).

3
The abbreviations used are:
LRP1
low density lipoprotein receptor-related protein 1
sLRP1
soluble LRP1
LC
LRP1 85-kDa light chain subunit
mLRP-II
mini-LRP1 receptor containing the second cluster of ligand binding repeats
mLRP-IV
mini-LRP1 receptor containing the fourth cluster of ligand binding repeats
RAP
receptor-associated protein.

REFERENCES

  • 1. Herz J., Strickland D. K. (2001) J. Clin. Invest. 108, 779–784 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Lillis A. P., Van Duyn L. B., Murphy-Ullrich J. E., Strickland D. K. (2008) Physiol. Rev. 88, 887–918 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Herz J., Kowal R. C., Goldstein J. L., Brown M. S. (1990) EMBO J. 9, 1769–1776 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Li Y., Marzolo M. P., van Kerkhof P., Strous G. J., Bu G. (2000) J. Biol. Chem. 275, 17187–17194 [DOI] [PubMed] [Google Scholar]
  • 5. Strickland D. K., Ashcom J. D., Williams S., Burgess W. H., Migliorini M., Argraves W. S. (1990) J. Biol. Chem. 265, 17401–17404 [PubMed] [Google Scholar]
  • 6. Kounnas M. Z., Church F. C., Argraves W. S., Strickland D. K. (1996) J. Biol. Chem. 271, 6523–6529 [DOI] [PubMed] [Google Scholar]
  • 7. Kounnas M. Z., Moir R. D., Rebeck G. W., Bush A. I., Argraves W. S., Tanzi R. E., Hyman B. T., Strickland D. K. (1995) Cell 82, 331–340 [DOI] [PubMed] [Google Scholar]
  • 8. Pietrzik C. U., Busse T., Merriam D. E., Weggen S., Koo E. H. (2002) EMBO J. 21, 5691–5700 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Loukinova E., Ranganathan S., Kuznetsov S., Gorlatova N., Migliorini M. M., Loukinov D., Ulery P. G., Mikhailenko I., Lawrence D. A., Strickland D. K. (2002) J. Biol. Chem. 277, 15499–15506 [DOI] [PubMed] [Google Scholar]
  • 10. Newton C. S., Loukinova E., Mikhailenko I., Ranganathan S., Gao Y., Haudenschild C., Strickland D. K. (2005) J. Biol. Chem. 280, 27872–27878 [DOI] [PubMed] [Google Scholar]
  • 11. Boucher P., Liu P., Gotthardt M., Hiesberger T., Anderson R. G., Herz J. (2002) J. Biol. Chem. 277, 15507–15513 [DOI] [PubMed] [Google Scholar]
  • 12. Boucher P., Gotthardt M., Li W. P., Anderson R. G., Herz J. (2003) Science 300, 329–332 [DOI] [PubMed] [Google Scholar]
  • 13. Spijkers P. P., da Costa Martins P., Westein E., Gahmberg C. G., Zwaginga J. J., Lenting P. J. (2005) Blood 105, 170–177 [DOI] [PubMed] [Google Scholar]
  • 14. Cao C., Lawrence D. A., Li Y., Von Arnim C. A., Herz J., Su E. J., Makarova A., Hyman B. T., Strickland D. K., Zhang L. (2006) EMBO J. 25, 1860–1870 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Muchowski P. J., Zhang L., Chang E. R., Soule H. R., Plow E. F., Moyle M. (1994) J. Biol. Chem. 269, 26419–26423 [PubMed] [Google Scholar]
  • 16. Zhang L., Plow E. F. (1996) J. Biol. Chem. 271, 18211–18216 [DOI] [PubMed] [Google Scholar]
  • 17. Zhang L., Plow E. F. (1997) J. Biol. Chem. 272, 17558–17564 [DOI] [PubMed] [Google Scholar]
  • 18. Mikhailenko I., Battey F. D., Migliorini M., Ruiz J. F., Argraves K., Moayeri M., Strickland D. K. (2001) J. Biol. Chem. 276, 39484–39491 [DOI] [PubMed] [Google Scholar]
  • 19. Striekland D. K., Ashcom J. D., Williams S., Battey F., Behre E., McTigue K., Battey J. F., Argraves W. S. (1991) J. Biol. Chem. 266, 13364–13369 [PubMed] [Google Scholar]
  • 20. Hahn-Dantona E., Ruiz J. F., Bornstein P., Strickland D. K. (2001) J. Biol. Chem. 276, 15498–15503 [DOI] [PubMed] [Google Scholar]
  • 21. Ashcom J. D., Tiller S. E., Dickerson K., Cravens J. L., Argraves W. S., Strickland D. K. (1990) J. Cell Biol. 110, 1041–1048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Clausen B. E., Burkhardt C., Reith W., Renkawitz R., Förster I. (1999) Transgenic Res. 8, 265–277 [DOI] [PubMed] [Google Scholar]
  • 23. Rohlmann A., Gotthardt M., Hammer R. E., Herz J. (1998) J. Clin. Invest. 101, 689–695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Lillis A. P., Greenlee M. C., Mikhailenko I., Pizzo S. V., Tenner A. J., Strickland D. K., Bohlson S. S. (2008) J. Immunol. 181, 364–373 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Willnow T. E., Orth K., Herz J. (1994) J. Biol. Chem. 269, 15827–15832 [PubMed] [Google Scholar]
  • 26. Trommsdorff M., Borg J. P., Margolis B., Herz J. (1998) J. Biol. Chem. 273, 33556–33560 [DOI] [PubMed] [Google Scholar]
  • 27. Ranganathan S., Liu C. X., Migliorini M. M., Von Arnim C. A., Peltan I. D., Mikhailenko I., Hyman B. T., Strickland D. K. (2004) J. Biol. Chem. 279, 40536–40544 [DOI] [PubMed] [Google Scholar]
  • 28. Ueda T., Rieu P., Brayer J., Arnaout M. A. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 10680–10684 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Zhou L., Lee D. H., Plescia J., Lau C. Y., Altieri D. C. (1994) J. Biol. Chem. 269, 17075–17079 [PubMed] [Google Scholar]
  • 30. Anderson D. C., Miller L. J., Schmalstieg F. C., Rothlein R., Springer T. A. (1986) J. Immunol. 137, 15–27 [PubMed] [Google Scholar]
  • 31. Van Strijp J. A., Russell D. G., Tuomanen E., Brown E. J., Wright S. D. (1993) J. Immunol. 151, 3324–3336 [PubMed] [Google Scholar]
  • 32. Migliorini M. M., Behre E. H., Brew S., Ingham K. C., Strickland D. K. (2003) J. Biol. Chem. 278, 17986–17992 [DOI] [PubMed] [Google Scholar]
  • 33. Lee D., Walsh J. D., Mikhailenko I., Yu P., Migliorini M., Wu Y., Krueger S., Curtis J. E., Harris B., Lockett S., Blacklow S. C., Strickland D. K., Wang Y. X. (2006) Molecular Cell 22, 423–430 [DOI] [PubMed] [Google Scholar]
  • 34. Fisher C., Beglova N., Blacklow S. C. (2006) Mol. Cell 22, 277–283 [DOI] [PubMed] [Google Scholar]
  • 35. Lee J. O., Rieu P., Arnaout M. A., Liddington R. (1995) Cell 80, 631–638 [DOI] [PubMed] [Google Scholar]
  • 36. Witthaut R., Farhood A., Smith C. W., Jaeschke H. (1994) J. Leukoc. Biol. 55, 105–111 [DOI] [PubMed] [Google Scholar]
  • 37. Vetvicka V., Thornton B. P., Ross G. D. (1996) J. Clin. Invest. 98, 50–61 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Cao C., Lawrence D. A., Strickland D. K., Zhang L. (2005) Blood 106, 3234–3241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Zhang L., Plow E. F. (1996) J. Biol. Chem. 271, 29953–29957 [DOI] [PubMed] [Google Scholar]
  • 40. Zhang L., Plow E. F. (1999) Biochemistry 38, 8064–8071 [DOI] [PubMed] [Google Scholar]
  • 41. Quinn K. A., Grimsley P. G., Dai Y. P., Tapner M., Chesterman C. N., Owensby D. A. (1997) J. Biol. Chem. 272, 23946–23951 [DOI] [PubMed] [Google Scholar]
  • 42. Gorovoy M., Gaultier A., Campana W. M., Firestein G. S., Gonias S. L. (2010) J. Leukoc. Biol. 88, 769–778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Overton C. D., Yancey P. G., Major A. S., Linton M. F., Fazio S. (2007) Circ. Res. 100, 670–677 [DOI] [PubMed] [Google Scholar]
  • 44. Hu L., Boesten L. S., May P., Herz J., Bovenschen N., Huisman M. V., Berbée J. F., Havekes L. M., van Vlijmen B. J., Tamsma J. T. (2006) Arterioscler. Thromb. Vasc. Biol. 26, 2710–2715 [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES